Allogeneic hematopoietic stem-cell transplantation is a curative therapy for a range of hematologic disorders. 1-3 Chronic graft-versus-host disease (GVHD) affects approximately half of transplant ...

People with severe symptoms of chronic graft versus host disease (GvHD) often need to use multiple treatments to manage their condition. In recent years, a new class of medicines known as kinase ...

Panelists discuss how the current treatment landscape for chronic graft-versus-host disease includes a range of immunosuppressive approaches, from traditional corticosteroids and calcineurin ...

New treatments for chronic GVHD are needed. Axatilimab, a monoclonal antibody, may attenuate the inflammation and fibrosis behind GVHD. New research findings are summarized in a short video.

In this randomized controlled trial, axatilimab effectively managed symptoms in patients with recurrent or refractory graft ...

Panelists discuss how axatilimab, a novel therapy for chronic graft-versus-host disease (cGVHD), functions through a unique mechanism of action compared to other treatments, highlighting its potential ...

New York, USA, Sept. 22, 2024 (GLOBE NEWSWIRE) -- Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight DelveInsight’s Graft versus ...

More information: Daniel Wolff et al, Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease, New England Journal of Medicine (2024). DOI: 10.1056/NEJMoa2401537 Mohamad Mohty ...

Results of the AGAVE-201 trial demonstrate a high incidence of response to axatilimab among patients with chronic graft-versus-host disease.

The anti-thymocyte globulin preparation used by Finke and colleagues could reduce the risk of acute and chronic graft-versus-host disease in patients receiving hematopoietic cell transplantation ...

Mesoblast Limited (ASX:MSB) is developing innovative allogeneic cellular medicines to treat complex inflammatory diseases. The company’s portfolio of Phase 3 product candidates includes therapies for ...

Health Check is renowned biotech journo Tim Boreham’s daily wrap covering morning movers and shakers of note in the ASX ...